Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs NiSource Inc Common Stock (NI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs NiSource Inc Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while NiSource Inc Common Stock trades at $41.35 (market cap $19.79B). The key difference: NiSource Inc Common Stock is far larger — about 20.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and NiSource Inc Common Stock pays a 2.91% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and NiSource Inc Common Stock for 6 Days on average.
| MRVI | NI | |
|---|---|---|
Market Cap | $977.37M | $19.79B |
Volume | 2,742,564 | 5,778,191 |
Sector | Health | Utilities |
52-Week High | $9.00 | $49.08 |
52-Week Low | $2.83 | $39.00 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $37.12B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NiSource (NI) trades at $41.49, up 0.63% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28, 2026. Fundamentals show solid profitability with a 13.15% net income margin and a P/E of 22.07. Recent news highlights dividend declarations and institutional buying interest, though the stock faces headwinds from storm recovery costs and interest rate sensitivity.
The outlook remains positive given analyst consensus with a $49.57 price target and 73% buy ratings. Key opportunities include data center demand growth and regulatory support, while risks involve volatile cash flows, high debt levels, and potential earnings pressure from operational disruptions. Investors should weigh the stable dividend yield against execution risks in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About NiSource Inc Common Stock
NiSource is an energy holding company whose regulated subsidiaries provide natural gas and electricity services. Its business is organized around gas distribution and electric operations in the United States.
Read more on NI →
